KR102415797B1 - Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체 - Google Patents
Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체 Download PDFInfo
- Publication number
- KR102415797B1 KR102415797B1 KR1020187026570A KR20187026570A KR102415797B1 KR 102415797 B1 KR102415797 B1 KR 102415797B1 KR 1020187026570 A KR1020187026570 A KR 1020187026570A KR 20187026570 A KR20187026570 A KR 20187026570A KR 102415797 B1 KR102415797 B1 KR 102415797B1
- Authority
- KR
- South Korea
- Prior art keywords
- disorder
- disease
- disorders
- compound
- htaar1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000694 effects Effects 0.000 title description 22
- 239000000556 agonist Substances 0.000 title description 14
- SONZLIIHTSKJMC-UHFFFAOYSA-N 5-ethyl-4-methyl-1h-pyrazole-3-carboxamide Chemical class CCC=1NN=C(C(N)=O)C=1C SONZLIIHTSKJMC-UHFFFAOYSA-N 0.000 title 1
- 102000011829 Trace amine associated receptor Human genes 0.000 title 1
- 108050002178 Trace amine associated receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000002253 acid Substances 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
- 208000035475 disorder Diseases 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 18
- 208000020925 Bipolar disease Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 201000000980 schizophrenia Diseases 0.000 claims description 12
- 201000009032 substance abuse Diseases 0.000 claims description 11
- 206010012335 Dependence Diseases 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 208000011117 substance-related disease Diseases 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 208000030814 Eating disease Diseases 0.000 claims description 8
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 235000014632 disordered eating Nutrition 0.000 claims description 8
- 231100000736 substance abuse Toxicity 0.000 claims description 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 208000002249 Diabetes Complications Diseases 0.000 claims description 6
- 206010012655 Diabetic complications Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 230000036760 body temperature Effects 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 230000013632 homeostatic process Effects 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 230000007958 sleep Effects 0.000 claims description 6
- XHHXGKRFUPEPFM-OAHLLOKOSA-N 5-ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide Chemical compound C(C)C1=C(C(=NN1)C(=O)NC1=CC=C(C=C1)[C@H]1CNCCO1)C XHHXGKRFUPEPFM-OAHLLOKOSA-N 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 230000027758 ovulation cycle Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000001195 anabolic effect Effects 0.000 claims description 4
- 239000008298 dragée Substances 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 101000890887 Homo sapiens Trace amine-associated receptor 1 Proteins 0.000 abstract description 23
- 102100040114 Trace amine-associated receptor 1 Human genes 0.000 abstract description 23
- 150000001412 amines Chemical class 0.000 abstract description 19
- 108020003175 receptors Proteins 0.000 abstract description 10
- 102000005962 receptors Human genes 0.000 abstract description 9
- 208000015114 central nervous system disease Diseases 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 44
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 37
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 36
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 28
- 239000013598 vector Substances 0.000 description 26
- 239000003814 drug Substances 0.000 description 25
- 230000003389 potentiating effect Effects 0.000 description 23
- 239000007787 solid Substances 0.000 description 22
- MFNJGDMJKJLUGC-UHFFFAOYSA-N 5-ethyl-4-methyl-1h-pyrazole-3-carboxylic acid Chemical compound CCC=1NN=C(C(O)=O)C=1C MFNJGDMJKJLUGC-UHFFFAOYSA-N 0.000 description 19
- 229960003920 cocaine Drugs 0.000 description 18
- 229940079593 drug Drugs 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000004031 partial agonist Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 102000004406 Trace amine-associated receptor 1 Human genes 0.000 description 10
- 108090000946 Trace amine-associated receptor 1 Proteins 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 9
- 238000000126 in silico method Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- -1 amine compounds Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000035 biogenic effect Effects 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 4
- QUSLQENMLDRCTO-YJNKXOJESA-N win 35428 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(F)C=C1 QUSLQENMLDRCTO-YJNKXOJESA-N 0.000 description 4
- PMDHIMMPXRSDML-UHFFFAOYSA-N 2-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC=N1 PMDHIMMPXRSDML-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- 208000025307 bipolar depression Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000010304 firing Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- RYLFTAZSKDUPAA-CYBMUJFWSA-N tert-butyl (2s)-2-(4-aminophenyl)morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCO[C@H]1C1=CC=C(N)C=C1 RYLFTAZSKDUPAA-CYBMUJFWSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- GQIRIWDEZSKOCN-UHFFFAOYSA-N 1-chloro-n,n,2-trimethylprop-1-en-1-amine Chemical compound CN(C)C(Cl)=C(C)C GQIRIWDEZSKOCN-UHFFFAOYSA-N 0.000 description 2
- LAWUBNJMRGMNQD-UHFFFAOYSA-N 1-phenylpyrazole-3-carboxylic acid Chemical compound N1=C(C(=O)O)C=CN1C1=CC=CC=C1 LAWUBNJMRGMNQD-UHFFFAOYSA-N 0.000 description 2
- SQSYNRCXIZHKAI-UHFFFAOYSA-N 2,6-dichloroisonicotinic acid Chemical compound OC(=O)C1=CC(Cl)=NC(Cl)=C1 SQSYNRCXIZHKAI-UHFFFAOYSA-N 0.000 description 2
- JRJLLMLYUFAZOM-UHFFFAOYSA-N 2,6-dimethylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(C)=N1 JRJLLMLYUFAZOM-UHFFFAOYSA-N 0.000 description 2
- ZGZMEKHQIZSZOH-UHFFFAOYSA-N 2-chloro-6-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(Cl)=N1 ZGZMEKHQIZSZOH-UHFFFAOYSA-N 0.000 description 2
- QXCOHSRHFCHCHN-UHFFFAOYSA-N 2-chloropyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(Cl)=C1 QXCOHSRHFCHCHN-UHFFFAOYSA-N 0.000 description 2
- ZHDRDZMTEOIWSX-UHFFFAOYSA-N 2-methyl-1,3-thiazole-4-carboxylic acid Chemical compound CC1=NC(C(O)=O)=CS1 ZHDRDZMTEOIWSX-UHFFFAOYSA-N 0.000 description 2
- KQRWYYSDIFOTTP-UHFFFAOYSA-N 2-phenyl-1,3-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=COC(C=2C=CC=CC=2)=N1 KQRWYYSDIFOTTP-UHFFFAOYSA-N 0.000 description 2
- IBUSLNJQKLZPNR-UHFFFAOYSA-N 2-phenyl-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=CC=CC=2)=N1 IBUSLNJQKLZPNR-UHFFFAOYSA-N 0.000 description 2
- LCALUFNLWHYTKX-UHFFFAOYSA-N 2-phenyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(=O)O)=CN=C1C1=CC=CC=C1 LCALUFNLWHYTKX-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- SGRSFFPRUYGFGN-UHFFFAOYSA-N 4-methyl-3-phenyl-1h-pyrazole-5-carboxylic acid Chemical compound CC1=C(C(O)=O)NN=C1C1=CC=CC=C1 SGRSFFPRUYGFGN-UHFFFAOYSA-N 0.000 description 2
- RNRLTTNKVLFZJS-UHFFFAOYSA-N 5,6-dichloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C(Cl)=C1 RNRLTTNKVLFZJS-UHFFFAOYSA-N 0.000 description 2
- GJLOKYIYZIOIPN-UHFFFAOYSA-N 5-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)C=N1 GJLOKYIYZIOIPN-UHFFFAOYSA-N 0.000 description 2
- XYLPLVUYPAPCML-UHFFFAOYSA-N 5-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(Cl)=C1 XYLPLVUYPAPCML-UHFFFAOYSA-N 0.000 description 2
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 2
- WMHSQCDPPJRWIL-UHFFFAOYSA-N 6-cyanopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(C#N)N=C1 WMHSQCDPPJRWIL-UHFFFAOYSA-N 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000639972 Homo sapiens Sodium-dependent dopamine transporter Proteins 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091008109 Pseudogenes Proteins 0.000 description 2
- 102000057361 Pseudogenes Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282695 Saimiri Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000018452 Torsade de pointes Diseases 0.000 description 2
- 208000002363 Torsades de Pointes Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 238000010976 amide bond formation reaction Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920002102 polyvinyl toluene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000003368 psychostimulant agent Substances 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000013577 regulation of ventricular cardiomyocyte membrane repolarization Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- RYLFTAZSKDUPAA-ZDUSSCGKSA-N tert-butyl (2r)-2-(4-aminophenyl)morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCO[C@@H]1C1=CC=C(N)C=C1 RYLFTAZSKDUPAA-ZDUSSCGKSA-N 0.000 description 2
- RYLFTAZSKDUPAA-UHFFFAOYSA-N tert-butyl 2-(4-aminophenyl)morpholine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCOC1C1=CC=C(N)C=C1 RYLFTAZSKDUPAA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- HGPJRCDUFZYVPC-JTQLQIEISA-N (2r)-2-(4-aminophenyl)morpholine-4-carboxylic acid Chemical compound C1=CC(N)=CC=C1[C@H]1OCCN(C(O)=O)C1 HGPJRCDUFZYVPC-JTQLQIEISA-N 0.000 description 1
- HGPJRCDUFZYVPC-SNVBAGLBSA-N (2s)-2-(4-aminophenyl)morpholine-4-carboxylic acid Chemical compound C1=CC(N)=CC=C1[C@@H]1OCCN(C(O)=O)C1 HGPJRCDUFZYVPC-SNVBAGLBSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
- AIXPUCAPNGLHLG-CYBMUJFWSA-N 2,6-dichloro-n-[4-[(2s)-morpholin-2-yl]phenyl]pyridine-4-carboxamide Chemical compound ClC1=NC(Cl)=CC(C(=O)NC=2C=CC(=CC=2)[C@@H]2OCCNC2)=C1 AIXPUCAPNGLHLG-CYBMUJFWSA-N 0.000 description 1
- VTDPVHWMMCOBMU-QGZVFWFLSA-N 2,6-dimethyl-N-[4-[(2S)-morpholin-2-yl]phenyl]pyridine-4-carboxamide Chemical compound Cc1cc(cc(C)n1)C(=O)Nc1ccc(cc1)[C@H]1CNCCO1 VTDPVHWMMCOBMU-QGZVFWFLSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UJWNXKANZXVFHO-OAHLLOKOSA-N 2-chloro-6-methyl-n-[4-[(2s)-morpholin-2-yl]phenyl]pyridine-4-carboxamide Chemical compound ClC1=NC(C)=CC(C(=O)NC=2C=CC(=CC=2)[C@@H]2OCCNC2)=C1 UJWNXKANZXVFHO-OAHLLOKOSA-N 0.000 description 1
- GCAJGMQHUUDISJ-CQSZACIVSA-N 2-chloro-N-[4-[(2S)-morpholin-2-yl]phenyl]pyridine-4-carboxamide Chemical compound ClC=1C=C(C(=O)NC2=CC=C(C=C2)[C@H]2CNCCO2)C=CN1 GCAJGMQHUUDISJ-CQSZACIVSA-N 0.000 description 1
- JEQFKXKYXLHVQE-CQSZACIVSA-N 2-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1,3-thiazole-4-carboxamide Chemical compound Cc1nc(cs1)C(=O)Nc1ccc(cc1)[C@H]1CNCCO1 JEQFKXKYXLHVQE-CQSZACIVSA-N 0.000 description 1
- VXZQQIGMIDKMCY-MRXNPFEDSA-N 2-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]pyridine-4-carboxamide Chemical compound Cc1cc(ccn1)C(=O)Nc1ccc(cc1)[C@H]1CNCCO1 VXZQQIGMIDKMCY-MRXNPFEDSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- TYKADUHZARVWIN-CQSZACIVSA-N 5,6-dichloro-N-[4-[(2S)-morpholin-2-yl]phenyl]pyridine-3-carboxamide Chemical compound Clc1cc(cnc1Cl)C(=O)Nc1ccc(cc1)[C@H]1CNCCO1 TYKADUHZARVWIN-CQSZACIVSA-N 0.000 description 1
- ASRMZZJJYSITLY-OAHLLOKOSA-N 5-chloro-N-[4-[(2S)-morpholin-2-yl]phenyl]pyridine-2-carboxamide Chemical compound ClC=1C=CC(=NC=1)C(=O)NC1=CC=C(C=C1)[C@H]1CNCCO1 ASRMZZJJYSITLY-OAHLLOKOSA-N 0.000 description 1
- DQIPENMWLDMNAT-OAHLLOKOSA-N 5-chloro-N-[4-[(2S)-morpholin-2-yl]phenyl]pyridine-3-carboxamide Chemical compound ClC=1C=C(C=NC=1)C(=O)NC1=CC=C(C=C1)[C@H]1CNCCO1 DQIPENMWLDMNAT-OAHLLOKOSA-N 0.000 description 1
- XHHXGKRFUPEPFM-HNNXBMFYSA-N 5-ethyl-4-methyl-N-[4-[(2R)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide Chemical compound C(C)C1=C(C(=NN1)C(=O)NC1=CC=C(C=C1)[C@@H]1CNCCO1)C XHHXGKRFUPEPFM-HNNXBMFYSA-N 0.000 description 1
- 210000002348 5-ht neuron Anatomy 0.000 description 1
- GZOOLXWQKURRPU-UHFFFAOYSA-N 6-(2,2,2-trifluoroethoxy)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(OCC(F)(F)F)N=C1 GZOOLXWQKURRPU-UHFFFAOYSA-N 0.000 description 1
- JNYLMODTPLSLIF-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)N=C1 JNYLMODTPLSLIF-UHFFFAOYSA-N 0.000 description 1
- QZQLOJFUTYSQRK-CQSZACIVSA-N 6-chloro-n-[4-[(2s)-morpholin-2-yl]phenyl]pyridine-3-carboxamide Chemical compound C1=NC(Cl)=CC=C1C(=O)NC1=CC=C([C@@H]2OCCNC2)C=C1 QZQLOJFUTYSQRK-CQSZACIVSA-N 0.000 description 1
- MQFBCPOULYPWAQ-MRXNPFEDSA-N 6-cyano-n-[4-[(2s)-morpholin-2-yl]phenyl]pyridine-3-carboxamide Chemical compound C=1C=C(C#N)N=CC=1C(=O)NC(C=C1)=CC=C1[C@H]1CNCCO1 MQFBCPOULYPWAQ-MRXNPFEDSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- KHUJTMQUNOGQKI-GOSISDBHSA-N C(C)C1=C(C(=NN1)C(=O)NC1=CC=C(C=C1)[C@H]1CN(CCO1)C(=O)OC(C)(C)C)C Chemical compound C(C)C1=C(C(=NN1)C(=O)NC1=CC=C(C=C1)[C@H]1CN(CCO1)C(=O)OC(C)(C)C)C KHUJTMQUNOGQKI-GOSISDBHSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101000788239 Homo sapiens Trace amine-associated receptor 2 Proteins 0.000 description 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100424373 Mus musculus Taar1 gene Proteins 0.000 description 1
- 241001503699 Muscovy duck parvovirus Species 0.000 description 1
- HGERVBWCKKJBMC-LJQANCHMSA-N N-[4-[(2S)-morpholin-2-yl]phenyl]-1-phenylpyrazole-3-carboxamide Chemical compound O=C(Nc1ccc(cc1)[C@H]1CNCCO1)c1ccn(n1)-c1ccccc1 HGERVBWCKKJBMC-LJQANCHMSA-N 0.000 description 1
- HZYCOVJPFLILNP-GOSISDBHSA-N N-[4-[(2S)-morpholin-2-yl]phenyl]-2-phenyl-1,3-oxazole-4-carboxamide Chemical compound O=C(Nc1ccc(cc1)[C@H]1CNCCO1)c1coc(n1)-c1ccccc1 HZYCOVJPFLILNP-GOSISDBHSA-N 0.000 description 1
- FMARCCRRUGZDDU-GOSISDBHSA-N N-[4-[(2S)-morpholin-2-yl]phenyl]-2-phenyl-1,3-thiazole-4-carboxamide Chemical compound O=C(Nc1ccc(cc1)[C@H]1CNCCO1)c1csc(n1)-c1ccccc1 FMARCCRRUGZDDU-GOSISDBHSA-N 0.000 description 1
- VNCZMBMKODMGRG-QGZVFWFLSA-N N-[4-[(2S)-morpholin-2-yl]phenyl]-2-phenyl-1,3-thiazole-5-carboxamide Chemical compound O=C(Nc1ccc(cc1)[C@H]1CNCCO1)c1cnc(s1)-c1ccccc1 VNCZMBMKODMGRG-QGZVFWFLSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101100424375 Rattus norvegicus Taar1 gene Proteins 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100025205 Trace amine-associated receptor 2 Human genes 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940125400 channel inhibitor Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- KLFVWQCQUXXLOU-UHFFFAOYSA-N epptb Chemical compound CCOC1=CC=CC(NC(=O)C=2C=C(C(N3CCCC3)=CC=2)C(F)(F)F)=C1 KLFVWQCQUXXLOU-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000002372 hematologic agent Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- ZQBNWMFBOSOOLX-UHFFFAOYSA-N hydron;n-[4-[1-[2-(6-methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide;dichloride Chemical compound Cl.Cl.CC1=CC=CC(CCN2CCC(CC2)C(=O)C=2C=CC(NS(C)(=O)=O)=CC=2)=N1 ZQBNWMFBOSOOLX-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000003379 hyperdopaminergic effect Effects 0.000 description 1
- 230000003528 hypoglutamatergic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- SVFXPTLYMIXFRX-BBRMVZONSA-N indatraline Chemical compound C1([C@@H]2C[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 SVFXPTLYMIXFRX-BBRMVZONSA-N 0.000 description 1
- 229950008889 indatraline Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- SYHGEUNFJIGTRX-UHFFFAOYSA-N methylenedioxypyrovalerone Chemical compound C=1C=C2OCOC2=CC=1C(=O)C(CCC)N1CCCC1 SYHGEUNFJIGTRX-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- MJEAXYXDZPINIR-OAHLLOKOSA-N n-[4-[(2s)-morpholin-2-yl]phenyl]-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide Chemical compound C1=NC(OCC(F)(F)F)=CC=C1C(=O)NC1=CC=C([C@@H]2OCCNC2)C=C1 MJEAXYXDZPINIR-OAHLLOKOSA-N 0.000 description 1
- UVEZVCKZYWIVDM-CQSZACIVSA-N n-[4-[(2s)-morpholin-2-yl]phenyl]-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C1=NC(C(F)(F)F)=CC=C1C(=O)NC1=CC=C([C@@H]2OCCNC2)C=C1 UVEZVCKZYWIVDM-CQSZACIVSA-N 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960001576 octopamine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 208000014321 polymorphic ventricular tachycardia Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000000718 qrs complex Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000034225 regulation of ventricular cardiomyocyte membrane depolarization Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020227021732A KR102537050B1 (ko) | 2016-03-17 | 2017-03-14 | Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16160790 | 2016-03-17 | ||
| EP16160790.8 | 2016-03-17 | ||
| PCT/EP2017/055885 WO2017157873A1 (en) | 2016-03-17 | 2017-03-14 | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227021732A Division KR102537050B1 (ko) | 2016-03-17 | 2017-03-14 | Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180117640A KR20180117640A (ko) | 2018-10-29 |
| KR102415797B1 true KR102415797B1 (ko) | 2022-07-04 |
Family
ID=55542549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187026570A Active KR102415797B1 (ko) | 2016-03-17 | 2017-03-14 | Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체 |
| KR1020227021732A Active KR102537050B1 (ko) | 2016-03-17 | 2017-03-14 | Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227021732A Active KR102537050B1 (ko) | 2016-03-17 | 2017-03-14 | Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체 |
Country Status (33)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020310539A1 (en) | 2019-07-11 | 2022-01-06 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted pyrazole derivatives |
| WO2021185878A1 (en) | 2020-03-19 | 2021-09-23 | F. Hoffmann-La Roche Ag | Salts and crystalline forms of a taar1 agonist |
| CN118251382A (zh) | 2021-11-08 | 2024-06-25 | 豪夫迈·罗氏有限公司 | 芳硝基化合物的催化氢化 |
| CN114288304A (zh) * | 2021-12-31 | 2022-04-08 | 江苏海洋大学 | 一种抗精神分裂症组合物及其应用 |
| AR129909A1 (es) | 2022-07-15 | 2024-10-09 | Hoffmann La Roche | Cetorreductasa mutante con mayor actividad de cetorreductasa así como métodos y usos de esta |
| KR20250044870A (ko) | 2022-08-12 | 2025-04-01 | 에프. 호프만-라 로슈 아게 | 5-에틸-4-메틸-n-[4-[(2s) 모르폴린-2-일]페닐]-1h-피라졸-3-카르복스아미드를 포함하는 약제학적 조성물 |
| EP4568654A1 (en) * | 2022-08-12 | 2025-06-18 | F. Hoffmann-La Roche AG | Use of co-processed excipients in continuous manufacturing of solid dosage forms |
| WO2024118488A1 (en) * | 2022-11-28 | 2024-06-06 | Sumitomo Pharma America, Inc. | 2-phenylmorpholine and 2-phenyl(thio)morpholine compounds and uses thereof |
| TW202444712A (zh) * | 2023-04-28 | 2024-11-16 | 大陸商江蘇豪森藥業集團有限公司 | 一種嗎啉雜環類化合物的鹽及其製備方法和應用 |
| WO2024258900A2 (en) * | 2023-06-13 | 2024-12-19 | University Of Georgia Research Foundation, Inc. | Plasmodium falciparum blood stage inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015165835A1 (en) | 2014-04-30 | 2015-11-05 | F. Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| WO2016016292A1 (en) | 2014-08-01 | 2016-02-04 | F. Hoffmann-La Roche Ag | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives |
Family Cites Families (178)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2731471A (en) | 1956-01-17 | Nxg hi | ||
| FR6551E (fr) | 1905-07-27 | 1906-12-17 | Carlo Chiesa | Séchoir à tambour rotatif, démontable et transportable, et fonctionnant à ciel ouvert, pour cocons, céréales, etc. |
| US2161938A (en) | 1934-07-31 | 1939-06-13 | Soc Of Chemical Ind | Imidazolines |
| US2457047A (en) | 1946-02-13 | 1948-12-21 | Monsanto Chemicals | 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same |
| DE842065C (de) | 1950-07-30 | 1952-06-23 | Bayer Ag | Verfahren zur Herstellung stickstoffhaltiger heterocyclischer Verbindungen |
| US2778836A (en) | 1954-04-02 | 1957-01-22 | Union Chimique Belge Sa | Substituted 2-methyl-delta2 imidazolines |
| US2744910A (en) | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts |
| US2744909A (en) | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-phenylbenzyl) imidazoline and acid addition salts |
| US2919274A (en) | 1957-09-17 | 1959-12-29 | Sahyun Melville | Amidines |
| GB877306A (en) | 1958-04-21 | 1961-09-13 | Pfizer & Co C | Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines |
| DE1083803B (de) | 1958-05-30 | 1960-06-23 | Bayer Ag | Verfahren zur Herstellung von Derivaten der Anthranil-N-carbonsaeure |
| DE1121054B (de) | 1960-11-23 | 1962-01-04 | Merck Ag E | Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen |
| US3202660A (en) | 1961-10-09 | 1965-08-24 | Boehringer Sohn Ingelheim | Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes |
| FR1355049A (fr) | 1962-04-12 | 1964-03-13 | Merck Ag E | Agent pour le traitement préalable de la peau en vue du rasage |
| DE1150180B (de) | 1962-04-12 | 1963-06-12 | Merck Ag E | Mittel zur Vorbehandlung der Haut fuer die Rasur |
| US3459763A (en) | 1966-01-25 | 1969-08-05 | Geigy Chem Corp | Certain amino imidazole derivatives |
| ES323985A1 (es) | 1966-02-26 | 1966-12-16 | Blade Pique Juan | Procedimiento para la obtenciën de derivados del imidazol |
| GB1180794A (en) | 1966-08-05 | 1970-02-11 | Boehringer Sohn Ingelheim | Novel Arylhydrazino-Imidazolines and Preparation Thereof |
| US3377247A (en) | 1967-04-28 | 1968-04-09 | Dow Chemical Co | Antidepressant method |
| US3586695A (en) | 1968-01-26 | 1971-06-22 | Dow Chemical Co | Substituted imidazolinyl indoles |
| US3577415A (en) | 1968-12-23 | 1971-05-04 | Robins Co Inc A H | 1-substituted-3-substituted phenoxypyrrolidines |
| US3577428A (en) | 1969-04-14 | 1971-05-04 | Colgate Palmolive Co | 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines |
| BE754935A (fr) | 1969-08-13 | 1971-02-17 | Hoechst Ag | 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation |
| US3818094A (en) | 1969-08-28 | 1974-06-18 | Boehringer Sohn Ingelheim | Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2) |
| US3622579A (en) | 1969-08-28 | 1971-11-23 | Boehringer Sohn Ingelheim | Derivatives of 2-anilino-1,3-diazacyclopentene-(2) |
| US3660423A (en) | 1970-02-13 | 1972-05-02 | Dow Chemical Co | 2-(substituted benzyl)methyl-2-imidazolines |
| GB1333471A (en) | 1971-01-27 | 1973-10-10 | Labaz | Imidazoline derivatives and process for preparing the same |
| DE2123243A1 (de) | 1971-05-11 | 1972-11-16 | Hupfauf, Lorenz, 8510 Fürth | Verfahren und Vorrichtung zum Schneiden oder Falten von Bahnen aus Papier-, Zellstoff od. dgl |
| DE2123246C2 (de) | 1971-05-11 | 1982-11-25 | Basf Ag, 6700 Ludwigshafen | 6-[p-(β-Phenyläthylaminoacetylamino)-phenyl]-4,5-dihydropyridazon-(3) |
| DE2253555A1 (de) | 1972-11-02 | 1974-05-09 | Hoechst Ag | Oxazolo-pyrimidine und verfahren zu ihrer herstellung |
| US3981814A (en) | 1973-09-18 | 1976-09-21 | Givaudan Corporation | Bacteriostatic substituted benzanilide compositions and methods for their use |
| CH609558A5 (en) | 1973-09-18 | 1979-03-15 | Givaudan & Cie Sa | Antibacterial composition |
| DE2446758C3 (de) | 1974-10-01 | 1979-01-04 | C.H. Boehringer Sohn, 6507 Ingelheim | 2-(2-Fluor-6-trifluormethylphenylimino)-imidazolidin, dessen Säureadditionssalze, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung bei der Bekämpfung der Hypertonie |
| US4125620A (en) | 1974-10-01 | 1978-11-14 | Boehringer Ingelheim Gmbh | 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof |
| US3992403A (en) | 1975-05-30 | 1976-11-16 | Schering Corporation | 2-Imidazolines and their use as hypoglycemic agents |
| GB1538097A (en) | 1976-01-26 | 1979-01-10 | Lafon Labor | Substituted phenyl-amidines |
| DE2849537C2 (de) | 1978-11-15 | 1983-03-17 | Beiersdorf Ag, 2000 Hamburg | Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| US4323570A (en) | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
| AU518569B2 (en) | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| US4311840A (en) | 1980-11-13 | 1982-01-19 | E. R. Squibb & Sons, Inc. | 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones |
| US4735959A (en) | 1981-01-10 | 1988-04-05 | Dr. Karl Thomae Gmbh | Carboxylic acid amides and pharmaceutical compositions containing them |
| DE3133887A1 (de) | 1981-08-27 | 1983-03-10 | Bayer Ag, 5090 Leverkusen | 2-arylhydrazino-2-imidazoline, deren acylderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von endo- und ektoparasiten |
| ES518818A0 (es) | 1982-01-27 | 1984-06-16 | Pfizer | Un procedimiento para la preparacion de una composicion ectoparasiticida, especialmente acaricida, o antihelmintica. |
| DE3302021A1 (de) | 1983-01-22 | 1984-07-26 | Basf Ag, 6700 Ludwigshafen | 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung |
| US4540705A (en) | 1983-03-14 | 1985-09-10 | Sterling Drug Inc. | Antidepressant imidazolines and related compounds |
| EP0166937B1 (en) | 1984-06-06 | 1991-08-28 | Abbott Laboratories | Adrenergic compounds |
| DK302185A (da) | 1984-07-05 | 1986-01-06 | Rolland Sa A | 2-amino-oxazoliner samt fremgangsmaade til deres fremstilling |
| JPS61233678A (ja) | 1985-04-09 | 1986-10-17 | Maruko Seiyaku Kk | ベンジルピペラジン誘導体 |
| US4665095A (en) | 1985-12-11 | 1987-05-12 | Abbott Laboratories | Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion |
| GB2215206B (en) | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| DE3830054A1 (de) | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| FR2645860B1 (fr) | 1989-04-14 | 1991-07-26 | Sarget Lab | Nouvelles aryloxymethyl-5 amino-2 oxazolines, syntheses et applications therapeutiques |
| FI894911A0 (fi) | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| DE69127002T2 (de) | 1990-01-31 | 1997-11-20 | Fuji Photo Film Co Ltd | Farbphotographisches Silberhalogenidmaterial |
| CA2211325C (en) | 1993-10-13 | 2006-08-15 | H. Joseph Horacek | Extended release clonidine formulation |
| EP0661266A1 (en) | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| DE19514579A1 (de) | 1995-04-20 | 1996-10-24 | Boehringer Ingelheim Kg | Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz |
| US5610174A (en) | 1995-06-02 | 1997-03-11 | Synaptic Pharmaceutical Corporation | Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence |
| ATE201016T1 (de) | 1995-06-09 | 2001-05-15 | Hoffmann La Roche | Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| HUP9904363A3 (en) | 1996-08-15 | 2000-12-28 | Schering Corp | Piperidine ether muscarinic antagonists and pharmaceutical compositions containing them |
| US5969137A (en) | 1996-09-19 | 1999-10-19 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| GB9625145D0 (en) | 1996-12-03 | 1997-01-22 | Smithkline Beecham Plc | Novel compounds |
| IL123232A0 (en) | 1997-02-11 | 1999-11-30 | Lilly Co Eli | Medicament for inhibiting glucose metabolism deterioration |
| US5866579A (en) | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
| AR016817A1 (es) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| US6184242B1 (en) | 1997-09-04 | 2001-02-06 | Syntex Usa (Llc) | 2-(substituted-phenyl)amino-imidazoline derivatives |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| BR9813381A (pt) | 1997-12-04 | 2000-10-03 | Allergan Sales Inc | "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c" |
| ATE239013T1 (de) | 1997-12-19 | 2003-05-15 | Lilly Co Eli | Hypoglykamische imidazoline derivate |
| AU3534699A (en) | 1998-04-23 | 1999-11-08 | Takeda Chemical Industries Ltd. | Naphthalene derivatives, their production and use |
| DE19826517B4 (de) | 1998-06-15 | 2006-03-23 | Baxter Healthcare S.A. | Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette |
| ES2150378B1 (es) | 1998-08-07 | 2001-07-01 | Esteve Labor Dr | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. |
| CA2246027A1 (en) | 1998-08-27 | 2000-02-27 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| US7183278B1 (en) | 1998-11-04 | 2007-02-27 | Meiji Seika Kaisha, Ltd. | Picolinamide derivative and harmful organism control agent comprising said picolinamide derivative as active component |
| GB9826412D0 (en) | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
| AU770042B2 (en) | 1998-12-18 | 2004-02-12 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6331541B1 (en) | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6777428B1 (en) | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
| AU761291B2 (en) | 1999-03-17 | 2003-05-29 | Astrazeneca Ab | Amide derivatives |
| AU778393B2 (en) | 1999-05-12 | 2004-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| US6355660B1 (en) | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| PE20010781A1 (es) | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
| JP2001151742A (ja) | 1999-11-26 | 2001-06-05 | Mitsui Chemicals Inc | アニリド誘導体及びそれを含有する抗不整脈剤 |
| FR2802533B1 (fr) | 1999-12-17 | 2002-02-15 | Sanofi Synthelabo | Phenoxypropanolamines, leur preparation et leur application en therapeutique |
| JP2001302643A (ja) | 2000-04-21 | 2001-10-31 | Suntory Ltd | 環状アミジン化合物 |
| JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| CA2422288A1 (en) | 2000-09-12 | 2002-03-21 | Oregon Health & Science University | Novel mammalian receptor genes and uses |
| EP1339694B1 (en) | 2000-11-14 | 2005-09-21 | F. Hoffmann-La Roche Ag | Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
| US7141590B2 (en) | 2000-12-29 | 2006-11-28 | Ucb Sa | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides |
| WO2002059080A2 (en) | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
| IL147921A0 (en) | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
| AU2003227437A1 (en) | 2002-04-23 | 2003-11-10 | Shionogi And Co., Ltd. | PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME |
| TW200306783A (en) | 2002-04-29 | 2003-12-01 | Fmc Corp | Pesticidal heterocycles |
| US7202244B2 (en) | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| UA77536C2 (en) | 2002-07-03 | 2006-12-15 | Lundbeck & Co As H | Secondary aminoaniline piperidines as mch1 antagonists and their use |
| KR100492252B1 (ko) | 2002-08-09 | 2005-05-30 | 한국화학연구원 | 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법 |
| US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| AU2003299797A1 (en) | 2002-12-19 | 2004-07-14 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
| US6933311B2 (en) | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2515780C (en) | 2003-02-20 | 2012-12-11 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| JP2006523692A (ja) | 2003-04-18 | 2006-10-19 | イーライ リリー アンド カンパニー | ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物 |
| WO2005014554A1 (en) | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
| JP4667384B2 (ja) | 2003-10-07 | 2011-04-13 | レノビス， インコーポレイテッド | イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法 |
| US20050197364A1 (en) | 2003-10-07 | 2005-09-08 | Kelly Michael G. | Amide compounds as ion channel ligands and uses thereof |
| BRPI0415833A (pt) | 2003-10-23 | 2007-01-02 | Hoffmann La Roche | derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos |
| AU2004308825B2 (en) | 2003-12-26 | 2011-03-10 | Masatoshi Hagiwara | Method of regulating phosphorylation of SR protein and antiviral agents comprising SR protein activity regulator as the active ingredient |
| WO2005087217A1 (en) | 2004-03-05 | 2005-09-22 | The General Hospital Corporation | Compositions and methods for modulating interaction between polypeptides |
| CA2564994A1 (en) | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
| WO2006009741A1 (en) | 2004-06-23 | 2006-01-26 | Eli Lilly And Company | Kinase inhibitors |
| CA2572874A1 (en) | 2004-07-02 | 2006-01-12 | Sankyo Company Limited | Urea derivative |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP2008509982A (ja) | 2004-08-16 | 2008-04-03 | プロシディオン・リミテッド | アリール尿素誘導体 |
| EP1820799A1 (en) | 2004-11-10 | 2007-08-22 | Wakamoto Pharmaceutical Co., Ltd. | 2,3,4,5-tetrahydro-1h-1,5-benzodiazepine derivative and medicinal composition |
| US20060111392A1 (en) | 2004-11-23 | 2006-05-25 | Wood Michael R | Substituted biaryl-carboxylate derivatives |
| JPWO2006070878A1 (ja) | 2004-12-28 | 2008-06-12 | アステラス製薬株式会社 | カルボン酸誘導体またはその塩 |
| GB0611907D0 (en) | 2006-06-15 | 2006-07-26 | Glaxo Group Ltd | Compounds |
| KR101345002B1 (ko) | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| US20080161355A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| EP1869012A1 (en) | 2005-04-05 | 2007-12-26 | Boehringer Ingelheim International Gmbh | Substituted benzylimidazoles useful for the treatment of inflammatory diseases |
| WO2006119411A1 (en) | 2005-05-03 | 2006-11-09 | Bayer Cropscience Ag | Insecticidal substituted aminoalkyl heterocyclic and heteroaryl derivatives |
| WO2007003967A2 (en) | 2005-07-06 | 2007-01-11 | Cambridge Semiconductor Limited | Switch mode power supply control systems |
| JP2007051121A (ja) | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンｄ合成酵素を阻害するピリミジン化合物 |
| US20100152188A1 (en) | 2005-08-05 | 2010-06-17 | Akella Satya Surya Visweswara Srinivas | Novel Heterocyclic Compounds |
| WO2007024944A1 (en) | 2005-08-25 | 2007-03-01 | Schering Corporation | Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists |
| HRP20100542T1 (hr) | 2005-09-16 | 2010-11-30 | Arrow Therapeutics Limited | Derivati bifenila i njihova uporaba za liječenje hepatitisa c |
| EP1945208A4 (en) | 2005-10-06 | 2011-08-03 | Univ Massachusetts | Composition and synthesis of new reagents for inhibition of hiv replication |
| US20070197529A1 (en) | 2005-12-01 | 2007-08-23 | Viviana Braude | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard |
| JP2007191471A (ja) | 2005-12-21 | 2007-08-02 | Sankyo Co Ltd | ウレア誘導体を含有する医薬 |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| BRPI0706759A2 (pt) | 2006-01-27 | 2011-04-05 | Hofmann La Roche Ag F | Uso de derivados de 4-imidazol para distúrbios do cns |
| CN101426774B (zh) | 2006-04-19 | 2012-04-25 | 安斯泰来制药有限公司 | 唑类甲酰胺衍生物 |
| PL2041093T3 (pl) | 2006-06-28 | 2010-09-30 | Glaxo Group Ltd | Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38 |
| CN101528710B (zh) | 2006-10-19 | 2012-11-07 | 弗·哈夫曼-拉罗切有限公司 | 氨基甲基-4-咪唑类 |
| EP2078004B1 (en) | 2006-10-31 | 2015-02-25 | Merck Sharp & Dohme Corp. | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| MX2009004786A (es) | 2006-10-31 | 2009-06-05 | Schering Corp | Derivados de anilinopiperazina y sus metodos de uso. |
| US20080221104A1 (en) | 2006-11-03 | 2008-09-11 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis |
| CN101568520A (zh) | 2006-12-26 | 2009-10-28 | 参天制药株式会社 | 具有脲结构的新型n-(2-氨基苯基)苯甲酰胺衍生物 |
| KR101174191B1 (ko) | 2007-02-02 | 2012-08-14 | 에프. 호프만-라 로슈 아게 | 중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린 |
| EP2121641B1 (en) | 2007-02-15 | 2014-09-24 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands |
| AU2008253118B2 (en) | 2007-05-22 | 2013-11-21 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| US8058299B2 (en) | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| JP5710251B2 (ja) | 2007-06-07 | 2015-04-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規ヘテロ環化合物およびその使用 |
| JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
| PA8783601A1 (es) | 2007-06-08 | 2009-01-23 | Janssen Pharmaceutica Nv | Derivados de piperidina/piperazina |
| KR20100039429A (ko) | 2007-08-02 | 2010-04-15 | 에프. 호프만-라 로슈 아게 | Ｃｎｓ 질환의 치료를 위한 벤즈아미드 유도체의 용도 |
| JP5341084B2 (ja) | 2007-08-03 | 2013-11-13 | エフ．ホフマン−ラ ロシュ アーゲー | Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
| JP2009094891A (ja) | 2007-10-10 | 2009-04-30 | Toshiba Corp | 半導体集積回路装置及びパターン検出方法 |
| US8093428B2 (en) | 2007-10-26 | 2012-01-10 | Janssen Pharmaceutica N.V. | Synthesis of quaternary salt compounds |
| CN101434570B (zh) | 2007-11-16 | 2011-02-02 | 上海医药工业研究院 | 吡咯烷衍生物及其制备方法和应用 |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| MX2011000464A (es) | 2008-07-24 | 2011-03-01 | Hoffmann La Roche | Derivados de 4,5-dihidro-oxazol-2-ilo. |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| EP2351744B1 (en) | 2008-10-17 | 2015-01-07 | Shionogi & Co., Ltd. | Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase |
| US8415333B2 (en) | 2009-02-24 | 2013-04-09 | Respiratorious Ab | Bronchodilating diazaheteroaryls |
| EP2411526A4 (en) | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | MODULATORS OF GANGLIOSID BIOSYNTHESIS |
| JP5381257B2 (ja) | 2009-04-09 | 2014-01-08 | ユニマテック株式会社 | 含フッ素ボロン酸エステル化合物の製造方法 |
| WO2010118347A2 (en) | 2009-04-10 | 2010-10-14 | Zacharon Pharmaceuticals, Inc. | O-linked glycan biosynthesis modulators |
| US20100311798A1 (en) | 2009-06-05 | 2010-12-09 | Decoret Guillaume | 2-aminooxazolines as taar1 ligands |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| PH12012501237A1 (en) | 2009-12-22 | 2012-11-26 | Celgene Corp | (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutic uses |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| ES2842399T3 (es) | 2009-12-22 | 2021-07-14 | Vertex Pharma | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa |
| US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| DE102011112317B3 (de) | 2011-09-02 | 2013-02-28 | Mühlbauer Ag | Wendevorrichtung für Identifikationsgegenstände |
| AU2013208104B2 (en) | 2012-01-09 | 2017-11-23 | X-Chem, Inc. | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof |
| EP2895477B1 (en) * | 2012-09-14 | 2017-11-01 | F. Hoffmann-La Roche AG | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease. |
| WO2014041106A1 (en) * | 2012-09-17 | 2014-03-20 | F. Hoffmann-La Roche Ag | Triazole carboxamide derivatives |
| CN104109165A (zh) | 2013-04-19 | 2014-10-22 | 四川海思科制药有限公司 | 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用 |
| PT3149002T (pt) | 2014-05-28 | 2018-06-18 | Hoffmann La Roche | Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo e 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como moduladores do taar1 |
| BR112017000160A2 (pt) | 2014-08-27 | 2017-10-31 | Hoffmann La Roche | derivados de azetidina substituidos como ligantes de taar |
| EP3882265B1 (en) | 2017-01-09 | 2022-11-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-mesothelin immunotherapy |
-
2017
- 2017-03-14 BR BR112018015389-3A patent/BR112018015389B1/pt active IP Right Grant
- 2017-03-14 SG SG11201807516UA patent/SG11201807516UA/en unknown
- 2017-03-14 JP JP2018545336A patent/JP6814814B2/ja active Active
- 2017-03-14 PE PE2018001346A patent/PE20181446A1/es unknown
- 2017-03-14 SG SG10201913878YA patent/SG10201913878YA/en unknown
- 2017-03-14 RS RS20201094A patent/RS60825B1/sr unknown
- 2017-03-14 PL PL17710286T patent/PL3430010T3/pl unknown
- 2017-03-14 MA MA43706A patent/MA43706B1/fr unknown
- 2017-03-14 CN CN201780014687.6A patent/CN108713019B/zh active Active
- 2017-03-14 CA CA3013696A patent/CA3013696C/en active Active
- 2017-03-14 SI SI201730407T patent/SI3430010T1/sl unknown
- 2017-03-14 MY MYPI2018001546A patent/MY195528A/en unknown
- 2017-03-14 AU AU2017234042A patent/AU2017234042B2/en active Active
- 2017-03-14 KR KR1020187026570A patent/KR102415797B1/ko active Active
- 2017-03-14 CR CR20180443A patent/CR20180443A/es unknown
- 2017-03-14 HR HRP20201405TT patent/HRP20201405T1/hr unknown
- 2017-03-14 DK DK17710286.0T patent/DK3430010T3/da active
- 2017-03-14 PT PT177102860T patent/PT3430010T/pt unknown
- 2017-03-14 HU HUE17710286A patent/HUE050986T2/hu unknown
- 2017-03-14 UA UAA201809608A patent/UA122881C2/uk unknown
- 2017-03-14 MX MX2018010622A patent/MX377836B/es unknown
- 2017-03-14 MA MA053755A patent/MA53755A/fr unknown
- 2017-03-14 EP EP20184122.8A patent/EP3757102A1/en active Pending
- 2017-03-14 WO PCT/EP2017/055885 patent/WO2017157873A1/en not_active Ceased
- 2017-03-14 EP EP17710286.0A patent/EP3430010B1/en active Active
- 2017-03-14 KR KR1020227021732A patent/KR102537050B1/ko active Active
- 2017-03-14 RU RU2018134262A patent/RU2731095C2/ru active
- 2017-03-14 LT LTEP17710286.0T patent/LT3430010T/lt unknown
- 2017-03-14 ES ES17710286T patent/ES2819830T3/es active Active
- 2017-03-15 AR ARP170100637A patent/AR107878A1/es unknown
- 2017-03-16 TW TW106108638A patent/TWI634117B/zh active
-
2018
- 2018-07-08 IL IL260473A patent/IL260473B/en active IP Right Grant
- 2018-07-17 CO CONC2018/0007515A patent/CO2018007515A2/es unknown
- 2018-07-23 ZA ZA2018/04943A patent/ZA201804943B/en unknown
- 2018-07-25 PH PH12018501588A patent/PH12018501588A1/en unknown
- 2018-09-10 CL CL2018002583A patent/CL2018002583A1/es unknown
- 2018-09-13 US US16/130,881 patent/US10508107B2/en active Active
-
2020
- 2020-06-11 US US16/898,827 patent/US11312711B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015165835A1 (en) | 2014-04-30 | 2015-11-05 | F. Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| WO2016016292A1 (en) | 2014-08-01 | 2016-02-04 | F. Hoffmann-La Roche Ag | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102415797B1 (ko) | Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체 | |
| US11661580B2 (en) | Method of inhibiting tau phosphorylation | |
| Rook et al. | Diverse effects on M1 signaling and adverse effect liability within a series of M1 ago-PAMs | |
| Boss et al. | Biomedical application of orexin/hypocretin receptor ligands in neuroscience | |
| Johnson et al. | Structure–Activity Relationship Study of N 6-(2-(4-(1 H-Indol-5-yl) piperazin-1-yl) ethyl)-N 6-propyl-4, 5, 6, 7-tetrahydrobenzo [d] thiazole-2, 6-diamine Analogues: Development of Highly Selective D3 Dopamine Receptor Agonists along with a Highly Potent D2/D3 Agonist and Their Pharmacological Characterization | |
| Garnsey et al. | Discovery of the potent and selective MC4R antagonist PF-07258669 for the potential treatment of appetite loss | |
| Wager et al. | Dopamine D3/D2 receptor antagonist PF-4363467 attenuates opioid drug-seeking behavior without concomitant D2 side effects | |
| Slack et al. | A novel bromine-containing paroxetine analogue provides mechanistic clues for binding ambiguity at the central primary binding site of the serotonin transporter | |
| US20130005709A1 (en) | Sulfone compounds as 5-ht6 receptor ligands | |
| Lacivita et al. | Design, synthesis, radiolabeling, and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl) piperazin-1-yl] ethyl]-3-methoxybenzamide, a potential positron emission tomography tracer for the dopamine D4 receptors | |
| HK1259672A1 (en) | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar | |
| HK1259672B (zh) | 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物 | |
| Calcaterra | ESTABLISHMENT AND UTILIZATION OF A DRUG DISCOVERY PLATFORM FOR KV11. 1-3.1, A NOVEL TARGET FOR THE TREATMENT OF SCHIZOPHRENIA | |
| Williams et al. | Activation of the mGlu5 Receptor for the Treatment of Schizophrenia and Cognitive-Deficit-Associated Disorders | |
| JP2006522742A (ja) | ピペラジンから距離をおいて配置したベンズヒドリル基から成る一群のカルシウムチャンネル阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180913 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200312 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20211110 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220520 |
|
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20220624 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220628 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20220629 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |